Komori
Share Issuance and Disposal4583Chiome Bioscience Inc.Pharmaceuticals

Notice Concerning the Large-Scale Exercise of the 23rd Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause)

With respect to the 23rd Stock Acquisition Rights (with Exercise Price Adjustment Clause), 1,446,900 shares were newly delivered between 1 June 2026 and 15 June 2026, reducing the unexercised balance from 53,206 to 38,737 rights.

Worth reading
55In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1446900
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数

Shares delivered since the beginning of the month: 1,446,900 shares (new shares: 1,446,900; treasury shares transferred: —)

発行済株式総数

Exercise ratio: 10.64% of the total number issued (exercised during this period)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
With an exercise price adjustment clause. The exercise price was ¥70.0 on 2 June, ¥68.1 on 4 June, ¥67.2 on 5 June, ¥68.1 on 8 June, ¥66.3 on 9 June, ¥66.3 on 10 June, ¥63.5 on 12 June and ¥63.5 on 15 June. The adjustment floor is Not disclosed
Number of Stock Acquisition Rights
Total number issued: 14,469 rights, equivalent to 10.64% of the total number issued. Unexercised balance as of the end of the previous month: 53,206 rights; current unexercised balance: 38,737 rights
Most recent equity financing
15 December 2025: Issuance of the 23rd Stock Acquisition Rights (with Exercise Price Adjustment Clause) (issue price and amount: Not disclosed)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofShares delivered since the beginning of the month: 1,446,900 shares (new shares: 1,446,900; treasury shares transferred: —)
Dilution RateExercise ratio: 10.64% of the total number issued (exercised during this period)
Total number of issued shares76,543,100 shares (as of the end of the previous month) → Not disclosed
Exercise priceWith an exercise price adjustment clause. The exercise price was ¥70.0 on 2 June, ¥68.1 on 4 June, ¥67.2 on 5 June, ¥68.1 on 8 June, ¥66.3 on 9 June, ¥66.3 on 10 June, ¥63.5 on 12 June and ¥63.5 on 15 June. The adjustment floor is Not disclosed
Number of Stock Acquisition RightsTotal number issued: 14,469 rights, equivalent to 10.64% of the total number issued. Unexercised balance as of the end of the previous month: 53,206 rights; current unexercised balance: 38,737 rights
Most recent equity financing15 December 2025: Issuance of the 23rd Stock Acquisition Rights (with Exercise Price Adjustment Clause) (issue price and amount: Not disclosed)
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the large-scale exercise of the 23rd Stock Acquisition Rights during the period from 1 June 2026 to 15 June 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Large-Scale Exercise of the 23rd Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) | Chiome Bioscience Inc. (4583) timely disclosure | Komori